NPS Pharmaceuticals, Inc. NPSP, a biopharmaceutical company
pioneering and delivering therapies that transform the lives of patients
with rare diseases worldwide, yesterday presented findings from the
company's pivotal Phase 3 study of Natpara® (recombinant human
parathyroid hormone 1-84, rhPTH(1-84)), known as REPLACE, suggesting the
investigational therapy has a beneficial effect on bone health in
patients with hypoparathyroidism. Investigators also reported findings
from the PARADOX burden of illness survey suggesting that patients with
hypoparathyroidism have a substantial burden of illness in the skeleton
and joints and experience bone-related symptoms and comorbidities
despite receiving standard care, such as calcium and active vitamin D.
Findings from REPLACE and PARADOX were presented in respective poster
sessions at the Annual
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in